The First Quarter Consolidated Financial Results for the Fiscal Year Ended March 31, 2021 (Japanese Accounting Standards)

August 4, 2020

Company name: SHOFU INC.

Listing: Tokyo Stock Exchange (First section)

Code number: 7979

URL: http://www.shofu.co.jp/

Representative: Noriyuki Negoro, Representative Director, President & Chief Executive Officer

Contact: Takahiro Umeda, Managing Executive Officer of Finance & General Manager of Finance Department

Scheduled date for filing of quarterly securities report: August 12, 2020

Scheduled commencement date of dividend payment: —
Supplementary documents for quarterly financial results: None
Quarterly financial results briefing: None

(All amounts are rounded down to the nearest million yen)

(% indicates changes from previous fiscal year)

1. Consolidated Financial Results for the First Quarter of Fiscal Year Ended March 31, 2021(April 1,2020 – June 30,2020)

(1) Consolidated Operating Results

| | Net sales | | Operating income | | Ordinary income | | Net income | |
|-------------------------------------|-----------------|--------|------------------|--------|-----------------|--------|-----------------|-------|
| | Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % |
| Three months ended June 30, 2020 | 4,877 | (24.5) | 128 | (76.2) | 80 | (83.9) | (58) | _ |
| Three months ended June 30, 2019 | 6,461 | 6.1 | 542 | 39.6 | 500 | 20.6 | 247 | (5.8) |

(Note) Comprehensive income: Three Months ended June 30, 2020

Three Months ended June 30, 2019

84 million yen (-%)(25) million yen (-%)

| | First Quarter | First Quarter |
|-------------------------------------|-------------------|-----------------------------|
| | Net income (loss) | Fully diluted |
| | per share | net income (loss) per share |
| | Yen | Yen |
| Three months ended June 30, 2020 | (3.61) | _ |
| Three months ended June 30, 2019 | 15.54 | 15.43 |

(2) Consolidated Financial Position

| | Total assets | Net assets | Equity ratio | Net assets per share |
|----------------------------------|-----------------|-----------------|--------------|----------------------|
| | Millions of yen | Millions of yen | % | Yen |
| Three months ended June 30, 2020 | 33,607 | 26,754 | 79.2 | 1,500.76 |
| Year ended March 31, 2020 | 29,834 | 23,936 | 79.7 | 1,491.81 |

(Reference) Shareholder's equity: Three Months ended June 30, 2020 26, Year ended March 31, 2020 23,

26,600 million yen 23,786 million yen

2. Dividends

| | Dividends per share | | | | | |
|------------------------------------------|----------------------|-----------------------|----------------------|----------|--------|--|
| | End of first quarter | End of second quarter | End of third quarter | Year-end | Annual | |
| | Yen | Yen | Yen | Yen | Yen | |
| Year ended March 31,2020 | _ | 10.00 | _ | 16.00 | 26.00 | |
| Year ended March 31,2021 | _ | | | | | |
| Year ending March 31,2021 (Forecasts) | | 8.00 | _ | 10.00 | 18.00 | |

(Notes) Revision to the dividend forecast during the current quarter: Yes

3. Consolidated Forecasts for the Fiscal Year Ending March 31, 2021. (April 1, 2020 – March 31, 2021)

(% indicates changes from previous fiscal year)

| | Net sale | es | Operating income | | Ordinary income | | Ordinary income | | Net income | | Net income | | Net income per share |
|-----------------------------------------------------------|-----------------|--------|------------------|--------|-----------------|--------|-----------------|--------|------------|--|------------|--|----------------------|
| | Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | Yen | | | | |
| Six months ending September 30,2020 (cumulative) | 10,473 | (22.0) | 315 | (77.7) | 245 | (80.2) | 51 | (93.4) | 3.05 | | | | |
| Year ending March 31,2021 | 22,838 | (12.5) | 1,378 | (37.6) | 1,179 | (40.7) | 771 | 9.5 | 44.57 | | | | |

(Notes) Revision during the current quarter to the performance forecasts: Yes

*Notes

(1) Changes in significant subsidiaries during the period (change in scope of consolidation): Yes

Addition: 1

Company name: SHOFU Products Vietnam Co., Ltd.

(2) Adoption of accounting methods specific to the preparation of quarterly financial statements: Yes

(3) Changes in accounting principles, procedures, or indication methods:

(a) Changes in accounting standards: None (b) Changes other than (a) above: None (c) Changes in accounting estimates: None (d) Retrospective restatements: None

(4) Number of shares outstanding (common stock)

(a) Number of shares outstanding at end of period (including treasury stock).

As of June 30, 2020: 17,894,089 shares
As of March 31, 2020: 16,114,089 shares
(b) Number of shares of treasury stock at end of period

As of June 30, 2020: 169,070 shares
As of March 31, 2020: 169,076 shares
(c) Average number of shares during the period
As of June 30, 2020: 16,257,981 shares
As of June 30, 2019: 15,904,694 shares

Please refer to the "Notice Regarding Results Forecast and Dividend Forecast" released on the date of this document with respect to our results forecast for the fiscal year ending March 31, 2021. The aforementioned forecasts have been calculated based upon currently available information and accordingly are not intended as a guarantee that the Company will achieve such results. Actual results may differ materially from the forecasts due to a variety of factors.

^{*} This quarterly earnings report is not subject to quarterly review by a certified public accountant or an audit firm.

^{*}Explanation concerning the appropriate use of business forecasts, and other special items (Forward-looking Statements)

Accompanying Materials—Contents

| 1. | Qualitative information related to financial results for the quarter under review | 2 |
|----|-----------------------------------------------------------------------------------------------------|---|
| | (1) Explanation of Business Results | |
| | (2) Explanation of Financial Position. | |
| | | |
| | (3) Explanation of Future Forecast Information including Consolidated Business Results Forecasts | 3 |
| 2. | Quarterly Consolidated Financial Statements and Primary Notes | 4 |
| | (1) Quarterly Consolidated Balance Sheets | 4 |
| | (2) Quarterly Consolidated Statements of Income and Comprehensive Income | |
| | (3) Notes to Quarterly Consolidated Financial Statements | 7 |
| | (Notes Relating to Assumptions for the Going Concern) | |
| | (Notes to Significant Changes in the Amounts of Shareholders' Equity) | 7 |
| | (Application of Special Accounting Processing in the Compilation of Quarterly Financial Statements) | 7 |
| | (Additional Information) | 7 |
| | (Segment Information,etc) | 8 |

1. Qualitative information related to financial results for the quarter under review

(1) Explanation of Business Results

During the first quarter of the consolidated fiscal year under review, future prospects for the global economy became uncertain amid developments that included a deteriorating employment and income environment in the US and Europe given substantial restrictions on economic activities with respective governments having imposed emergency measures such as lockdowns and stay-at-home orders in major cities due to the spread of the novel coronavirus. The Japanese economy has also been marked by growing concerns of an economic downturn amid a scenario whereby individual consumption and corporate earnings have been deteriorating significantly underpinned by a mounting atmosphere of self-restraint, with seemingly no end in sight with respect to the COVID-19 pandemic.

Under such circumstances, the Company has concluded a new business and capital tie-up agreement with Mitsui Chemicals Inc. ("MCI") in order to further strengthen business and capital tie-ups relating to the dental materials businesses with respect to which agreement had been concluded with MCI and its subsidiary Sun Medical Co., Ltd. ("Sun Medical").

The Company has become an equity-method affiliate of MCI as a result of MCI now holding 20% of the total number of shares issued by the Company upon the Company having issued new shares to MCI by means of third-party allotment, in conjunction with the new business and capital tie-up agreement. Moreover, Sun Medical has been made an equity-method affiliate of the Company upon having acquired its shares from MCI (20% of the total number of issued shares) by means of bilateral transaction.

The Company Group posted net sales of 4,877 million yen for the quarter under review, a decrease of 1,583 million yen (24.5%) from the corresponding period of the previous consolidated fiscal year due to effects of the novel coronavirus. Overseas sales decreased by 1,247 million yen (42.0%) from the corresponding period of the previous consolidated fiscal year to 1,720 million yen (35.3% of net sales).

Operating income decreased by 413 million yen (76.2%) from the corresponding period of the previous consolidated fiscal year to 128 million yen despite a decrease in selling, general, and administrative expenses.

Ordinary income decreased by 420 million yen (83.9%) from the corresponding period of the previous consolidated fiscal year to 80 million yen largely as a result of having posted expenses associated with issuance of new shares by means of third-party allotment as non-operating expenses.

Profit attributable to owners of parent, after deducting tax expenses, was a loss of 58 million yen, a decrease of 305 million yen, from the corresponding period of the previous consolidated fiscal year.

(Dental business)

Domestically, the "EyeSpecial C-IV," a digital oral cavity photography device, and "SHOFU BLOCK HC SUPER HARD," a resin material for dental cutting processing, which was launched during the previous consolidated fiscal year, etc. contributed to sales. However, sales decreased from the corresponding period of the previous consolidated fiscal year given fewer opportunities to provide dental care due to effects of the novel coronavirus, and also as a result of restrictions having been imposed on sales activities. Looking overseas, sales decreased from the corresponding period of the previous consolidated fiscal year given more serious effects of the novel coronavirus that led to lackluster results in each region, as well as effects of foreign currency exchange rates.

As a result of these factors, net sales for the quarter under review decreased 1,504 million yen (25.7%) from the corresponding period of the previous consolidated fiscal year to 4,341 million yen, and operating income decreased 438 million yen (84.1%) to 82 million yen.

(Nail care business)

Domestically, sales decreased from the corresponding period of the previous consolidated fiscal year owing to lackluster results of products for professional manicurists largely due to cancellations of major exhibitions, and despite growth in sales of "by Nail Labo" gel nail products for home use due to effects of the novel coronavirus. Looking overseas, sales increased from the corresponding period of the previous consolidated fiscal year, driven by strong online sales in the US due to active sales promotion activities through social networking sites (SNS) and by sales in Taiwan of our mainstay gel nail products "L·E·D Gel Presto."

As a result of these factors, net sales for the quarter under review decreased 77 million yen (13.1%) from the corresponding period of the previous consolidated fiscal year to 517 million yen. Operating income was 42 million yen,a year-on-year increase of 24 million yen(142.9%), owing to a reduction in selling, general, and administrative expenses.

(Other businesses)

SHOFU PRODUCTS KYOTO INC., a Group company, uses its dental abrasives manufacturing technology to manufacture and sell industrial abrasives. Net sales in the "other businesses" segment for the quarter under review decreased 1 million yen (5.4%) from the corresponding period of the previous consolidated fiscal year to 19 million yen, and operating income was almost same as the previous consolidated fiscal year 2 million yen.

(2) Explanation of Financial Position

Total assets at the end of the quarter under review increased by 3,773 million yen from the end of the previous consolidated fiscal year to 33,607 million yen. The increase in investment securities due to the acquisition of Sun Medical shares is the main factor.

Liabilities increased by 955 million yen to 6,853 million yen. The primary factor was an increase in long term loans payable.

Net assets increased by 2,817 million yen to 26,754 million yen. The primary factors were increases in capital stock and capital surplus associated with issuance of new shares by means of third-party allotment.

As a result of the above, the capital-to-assets ratio fell to 79.2%, a decrease of 0.5 points from the end of the previous consolidated fiscal year.

(3) Explanation of Future Forecast Information including Consolidated Business Results Forecasts Please refer to the "Notice Regarding Results Forecast and Dividend Forecast" released on the date of this document with respect to our results forecast for the fiscal year ending March 31, 2021.

2. Quarterly Consolidated Financial Statements and Primary Notes

(1)Quarterly Consolidated Balance Sheets

| (1)Quarterly Consondated Balance Sneets | | (Millions of yen) |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|------------------------------------------------------------------|
| Cash and deposits Notes and accounts receivable-trade Securities Merchandises and finished goods Work in process Raw materials and supplies Other Allowance for doubtful accounts Total current assets oncurrent assets Property,plant and equipment Buildings and structures Accumulated depreciation Buildings and structures, net Other Accumulated depreciation Other, net Total property,plant and equipment Intangible assets Investments and other assets Net defined benefit asset Other Allowance for doubtful accounts Total investments and other assets | Previous fiscal year (as of March 31,2020) | End of First Quarter of Fiscal 2020. (as of June 30, 2020) |
| Assets | | |
| Current assets | | |
| Cash and deposits | 4,862 | 5,157 |
| Notes and accounts receivable-trade | 3,187 | 2,716 |
| Securities | 5 | 5 |
| Merchandises and finished goods | 4,713 | 5,283 |
| Work in process | 1,045 | 1,133 |
| Raw materials and supplies | 972 | 978 |
| Other | 646 | 722 |
| Allowance for doubtful accounts | (16) | (26) |
| Total current assets | 15,416 | 15,972 |
| Noncurrent assets | | |
| Property, plant and equipment | | |
| Buildings and structures | 8,692 | 9,206 |
| Accumulated depreciation | (5,575) | (5,530) |
| Buildings and structures, net | 3,116 | 3,675 |
| Other | 11,195 | 10,741 |
| Accumulated depreciation | (6,623) | (6,690) |
| Other, net | 4,572 | 4,050 |
| Total property, plant and equipment | 7,689 | 7,726 |
| Intangible assets | 310 | 301 |
| Investments and other assets | | |
| Investment securities | 5,648 | 8,800 |
| Net defined benefit asset | 361 | 361 |
| Other | 418 | 456 |
| Allowance for doubtful accounts | (10) | (11) |
| Total investments and other assets | 6,417 | 9,607 |
| Total non-current assets | 14,417 | 17,635 |
| Total assets | 29,834 | 33,607 |

| | | (Millions of yen) | |
|-------------------------------------------------------|--------------------------------------------|------------------------------------------------------------|--|
| | Previous fiscal year (as of March 31,2020) | End of First Quarter of Fiscal 2020. (as of June 30, 2020) | |
| Liabilities | | | |
| Current liabilities | | | |
| Accounts payable-trade | 831 | 584 | |
| Short-term loans payable | 433 | 132 | |
| Current portion of long-term loans payable | 125 | 325 | |
| Income taxes payable | 202 | 155 | |
| Provision for directors' bonuses | 50 | 13 | |
| Other | 2,037 | 2,354 | |
| Total current liabilities | 3,680 | 3,564 | |
| Noncurrent liabilities | - | | |
| Long-term loans payable | 678 | 1,659 | |
| Net defined benefit liability | 236 | 233 | |
| Other | 1,302 | 1,394 | |
| Total noncurrent liabilities | 2,216 | 3,288 | |
| Total liabilities | 5,897 | 6,853 | |
| Net assets | | | |
| Shareholders' equity | | | |
| Capital stock | 4,474 | 5,968 | |
| Capital surplus | 4,586 | 6,080 | |
| Retained earnings | 12,840 | 12,525 | |
| Treasury shares | (185) | (185) | |
| Total shareholders' equity | 21,715 | 24,390 | |
| Accumulated other comprehensive income | | | |
| Valuation difference on available-for-sale securities | 2,465 | 2,648 | |
| Foreign currency translation adjustment | (495) | (534) | |
| Remeasurements of defined benefit plans | 100 | 97 | |
| Total accumulated other comprehensive income | 2,071 | 2,210 | |
| Subscription rights to shares | 116 | 116 | |
| Non-controlling interests | 33 | 37 | |
| Total net assets | 23,936 | 26,754 | |
| Total liabilities and net assets | 29,834 | 33,607 | |

(2) Quarterly Consolidated Statements of Income and Comprehensive Income Quarterly Consolidated Statements of Income

| Quarterly Consonanted Statements of Income | | (Millions of yen) |
|---------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|
| | First Quarter of Fiscal 2019 (from April 1, 2019 to June 30, 2019) | First Quarter of Fiscal 2020 (from April 1, 2020 to June 30, 2020) |
| Net sales | 6,461 | 4,877 |
| Cost of sales | 2,813 | 2,187 |
| Gross profit | 3,647 | 2,690 |
| Selling, general, and administrative expenses | 3,105 | 2,561 |
| Operating profit | 542 | 128 |
| Non-operating income | | |
| Interest income | 2 | 3 |
| Dividend income | 54 | 45 |
| Membership fee income | 22 | 5 |
| Foreign exchange gains | - | 10 |
| Other | 23 | 62 |
| Total non-operating income | 102 | 127 |
| Non-operating expenses | | |
| Interest expenses | 0 | 1 |
| Sales discounts | 41 | 40 |
| Membership fee | 21 | 12 |
| Share issuance costs | - | 98 |
| Foreign exchange losses | 66 | - |
| Other | 13 | 22 |
| Total non-operating expenses | 144 | 175 |
| Ordinary profit | 500 | 80 |
| Profit before income taxes | 500 | 80 |
| Income taxes | 253 | 136 |
| Profit (loss) | 246 | (55) |
| Profit (loss) attributable to non-controlling interests | (0) | 2 |
| Profit (loss) attributable to owners of parent | 247 | (58) |

Quarterly Consolidated Statements of Comprehensive Income

| | | (Millions of yen) |
|----------------------------------------------------------------|------------------------------|------------------------------|
| | First Quarter of Fiscal 2019 | First Quarter of Fiscal 2020 |
| | (from April 1, 2019 | (from April 1, 2020 |
| | to June 30, 2019) | to June 30, 2020) |
| Profit (loss) | 246 | (55) |
| Other comprehensive income | | |
| Valuation difference on available-for-sale securities | (183) | 182 |
| Foreign currency translation adjustment | (86) | (38) |
| Remeasurements of defined benefit plans, net of tax | (1) | (3) |
| Total other comprehensive income | (272) | 140 |
| Comprehensive income | (25) | 84 |
| Comprehensive income attributable to: | | |
| Comprehensive income attributable to owners of parent | (24) | 81 |
| Comprehensive income attributable to non-controlling interests | (0) | 3 |

(3) Notes to Quarterly Consolidated Financial Statements

(Notes Relating to Assumptions for the Going Concern) Not applicable.

(Notes to Significant Changes in the Amounts of Shareholders' Equity)

On May 14, 2020, the Company concluded a business and capital tie-up agreement with Mitsui Chemicals Inc. On June 15, 2020, the Company accordingly received proceeds for the capital increase by way of third-party allotment from Mitsui Chemicals Inc. As a result, capital stock and capital reserve each increased by 1,494 million yen during the first quarter of the consolidated fiscal year under review.

(Application of Special Accounting Processing in the Compilation of Quarterly Financial Statements). (Calculation of tax expenses)

To calculate tax expenses, we made a reasonable estimate of the effective tax rate after the application of tax effect accounting to current net income before tax for the current consolidated fiscal year and then multiplied the current net income before tax for the quarter under review by the estimated effective tax rate. However, where use of the estimated effective tax rate to calculate tax expenses would result in an unreasonable figure, we have used the legal effective tax rate instead.

(Additional Information)

(Application of Tax Effect Accounting with regard to the Transition from the Consolidated Taxation System to the Group Tax Sharing System)

The Company and some of its domestic consolidated subsidiaries do not apply Paragraph 44 of the "Implementation Guidance on Tax Effect Accounting" (ASBJ Guidance No. 28, February 16, 2018) to items revised under the non-consolidated taxation system in connection with the transition to the group tax sharing system established under the "Act for Partial Amendment of the Income Tax Act, etc." (Act No. 8 of 2020) and the transition to the group tax sharing system otherwise, per application of Paragraph 3 of the "Practical Solution on the Treatment of Tax Effect Accounting for the Transition from the Consolidated Taxation System to the Group Tax Sharing System" (PITF No. 39, March 31, 2020), but instead apply the pre-amendment income tax provisions to the amount of deferred tax assets and deferred tax liabilities.

(Segment Information, etc)

Previous fiscal year (April 1, 2019 – June 30, 2019)

1. Information regarding sales, gains (losses) by reportable segment

(Millions of yen)

| | Reporting segment | | | Adjustment | Consolidated financial | |
|---------------------------------|--------------------|--------------------|------------------|------------|------------------------|------------------|
| | Dental Business | Nail care business | Other businesses | Total | *1 | statements *2 |
| Net sales | | | | | | |
| (1) Sales to external customers | 5,846 | 595 | 20 | 6,461 | - | 6,461 |
| (2) Internal sales or transfers | - | - | 1 | 1 | (1) | - |
| Total | 5,846 | 595 | 21 | 6,462 | (1) | 6,461 |
| Segment profit | 521 | 17 | 2 | 541 | 1 | 542 |

^{*1} The ¥1 million adjustment to segment profit/loss serves to cancel out transactions between segments.

Fiscal year under review (April 1, 2020 – June 30, 2020)

1. Information regarding sales, gains (losses) by reportable segment

(Millions of yen)

| | | Reporting segment | | | | Consolidated financial |
|---------------------------------|--------------------|--------------------|------------------|-------|-----|------------------------|
| | Dental Business | Nail care business | Other businesses | Total | *1 | statements *2 |
| Net sales | | | | | | |
| (1) Sales to external customers | 4,341 | 517 | 19 | 4,877 | - | 4,877 |
| (2) Internal sales or transfers | - | - | 1 | 1 | (1) | - |
| Total | 4,341 | 517 | 20 | 4,878 | (1) | 4,877 |
| Segment profit(loss) | 82 | 42 | 2 | 127 | 1 | 128 |

^{*1} The ¥1 million adjustment to segment profit/loss serves to cancel out transactions between segments.

^{*2} Segment profit equals the operating income on quarterly consolidated financial statements.

^{*2} Segment profit equals the operating income on quarterly consolidated financial statements.